Heavy new drug rejected by the United States, Kangfang Biotechnology's Xia Yu: the most depressed time in 14 years

Economic Observer Follow 2026-11-16 08:28

Economic Observer reporter Liu Xiaonuo

To be honest, this is the most frustrating time for me since Kangfang Biotechnology was founded 14 years ago, "said Xia Yu, founder and chairman of Kangfang Biotechnology (09926. HK), during a conference call on the evening of November 15th.

On the same day, Summit, the overseas partner of Kangfang Biotechnology, announced that the marketing application of Ecovacis had not been approved by the US Food and Drug Administration (FDA).

Yvoxi is a star anti-cancer drug known for defeating the "global drug king" in a Chinese clinical trial (HARMONI-2). It is the core product of Kangfang Biotechnology, approved for market in China in May 2024.

The progress of Yvoxi's US IPO has always been the focus of attention for investors and the industry. In December 2022, Kangfang Biotechnology reached a potential cooperation agreement with Summit for a total transaction value of $5 billion, with Summit responsible for the development of Ecovaci overseas.

In January 2026, the FDA accepted Summit's marketing application for Ecovacil, which was primarily based on the global multicenter phase III clinical trial HARMONI. The indication was locally advanced/metastatic non-small cell lung cancer treated with EGFR-TKI.

According to the announcement released by Summit on November 15th, the FDA believes that although Ecovacil has achieved progression free survival (PFS) benefits, there is a lack of statistically significant overall survival (OS) benefits, and existing evidence does not yet support a positive benefit risk assessment.

Summit also stated that it will continue to develop Ecovaci. At present, Summit is leading three other overseas phase III clinical trials of Ecovaci, and one important head to head clinical trial, HARMONI-3, has also completed patient enrollment.

Xia Yu said, "In the past, when we had good news, the stock price would also fluctuate. But now it's not really good news, maybe the volatility won't be too big. I also think that if we miss the opportunity, it's a blessing in disguise. Perhaps the opportunities in the future will be better

She stated that Kangfang Biotechnology will be prepared and take timely measures such as repurchases to strive for market stability.

Regret in overall survival data

At the meeting, Xia Yu explained the OS issues of the HARMONI clinical trial.

HARMONI is a global Phase III study that builds upon the previous Chinese Phase III study HARMONI-A conducted by Kangfang Biotechnology. In December 2022, when Kangfang Biotechnology reached a cooperation agreement with Summit, HARMONI-A had already completed patient enrollment in China. In the global study of HARMONI, both parties hope to include eligible Chinese patients and then sequentially enroll overseas patients.

Xia Yu admitted that this clinical trial design is actually a bit clever. After communicating with the FDA, they agreed to this plan and explicitly required that the study achieve statistical significance of OS in order to be approved.

She stated that HARMONI has encountered many difficulties in conducting its research. At that time, Yvoxi had no experience in using drugs for overseas patients, and recruiting patients for overseas research also faced difficulties. There were also differences in the enrollment time between Chinese and overseas patients.

In the end, HARMONI achieved statistically significant PFS results, but in the predetermined formal OS analysis, although a survival benefit trend was observed, it did not reach statistical significance. Afterwards, Summit continued to extend patient follow-up time and conducted OS supplementary analysis, achieving nominally statistically significant results. Xia Yu explained that HARMONI's overseas data is consistent with Chinese data, and subsequent analysis has also shown that OS benefits, but the subsequent analysis lacks formal statistical validity, which is regrettable.

Nevertheless, Summit still chose to submit a marketing application to the FDA. This decision took into account that there was still room for improvement in the existing treatment methods for the patient population at that time, especially in terms of safety, tolerability, and other aspects. Summit believes that the efficacy and safety data of Ivosi may still support a new treatment option.

In the end, the FDA did not back down.

Subsequent key development of combination drugs

Kangfang Biotechnology positions Ecovacil as the cornerstone drug for the next generation of tumor immunotherapy.

In the clinical trial HARMONI-2 in China, Ivosi defeated the gold standard "K drug" of tumor immunotherapy head to head. K-drug ", also known as Merck's pembrolizumab, is one of the world's best-selling anti-cancer drugs.

According to Summit's disclosure on November 4th, including HARMONI, Summit has conducted four global phase III clinical studies of Iverxes, as well as one phase II/III and one phase II study. In addition, cancer research collaboration organizations in Europe and the United States have initiated one Phase III and one Phase II/III study, respectively, involving the use of Ivoxidan and combination therapy regimens.

HARMONI-3 is also highly regarded as a phase III clinical trial worldwide, which compares the efficacy of combination chemotherapy with Ecovacil and "K-drug" in a head to head manner. Its indication is for first-line advanced non-small cell lung cancer. At present, both squamous cell carcinoma and non squamous cell carcinoma cohorts in this study have completed patient enrollment and are expected to reach the conditions for conducting major PFS analysis in the fourth quarter of 2026 and the first half of 2027, respectively.

With the continuous progress of Eversion, multinational pharmaceutical companies have gradually acquired Chinese PD-1/VEGF assets. Merck&Co. has reached deals with Lixin Pharmaceuticals, Pfizer and Sansheng Pharmaceuticals (01530. HK), and AbbVie and Rongchang Biotechnology (688331. SH/09995. HK), with potential total transaction amounts of billions of dollars.

Prior to the FDA's rejection decision, Summit also welcomed an important strategic investor. In October 2026, AstraZeneca invested $2 billion in Summit, obtaining equity equivalent to approximately 12% of Summit's existing common stock, which is approximately 10.6% on a fully diluted basis. The two parties have reached a clinical research cooperation and plan to evaluate the efficacy of the combination therapy of Ivosi and its antibody conjugated drugs (ADCs) in the treatment of cancer.

At present, the development of multiple other PD-1/VEGF drugs has also entered phase III clinical trials. This rejection may shorten Yvoxi's overseas first mover advantage.

Xia Yu admitted that this incident is a hurdle for both Kangfang Biotechnology and Summit. She hopes that in a few years, this setback will be a 'very small event'.

Regarding the results of this review, Robert Duggan, Chairman and Co CEO of Summit, expressed regret for those patients and their families who are waiting for further treatment. We believe that the global Phase III HARMONI study has provided sufficient evidence to demonstrate that this treatment plan has the potential to meet the treatment needs of these patients. ”

Duggan pointed out that there are five positive Phase III research results between Summit and Kangfang Biotechnology. Our determination to explore the potential of ivonescimab and advance its research and development remains unchanged... We will continue to carry out this massive clinical research and development work. ”

Next, they will continue to advance the global Phase III clinical study of HARMONI-3, and will also focus on promoting the combination therapy of ivoxil with multiple anti-tumor drugs, including AstraZeneca's ADC drug and Revolution Medicines' RAS inhibitor.


Reporter from the Health News Department
A listener who wants to become an observer.
Pay attention to companies, people, and events in the fields of medicine and health. Please contact liuxiaonuo@eeo.